EUVIMEDEUVIMED entdecken
Crossref

Impact of graft‐versus‐host disease prophylaxis on second primary malignancies after allogeneic haematopoietic stem cell transplantation

Nihar Desai iD, Eshrak Al-Shaibani, Tommy Alfaro-Moya, Arjun D Law iD, Wilson Lam, Mats Remberger, Ivan Pasic, Igor Novitzky-Basso, Auro Viswabandya, Dennis D Kim iD, Rajat Kumar, Jeffrey H Lipton und 2 weitere

British Journal of Haematology · 2025

DOI: 10.1111/bjh.70006 ↗

Kurz gefasst

Fachartikel in der Zeitschrift British Journal of Haematology, 2025. Verfasst von Nihar Desai und 13 weiteren Autor:innen. Beteiligte Einrichtung: Hans Messner Allogeneic Transplant Program, Division of Medical Oncology and Haematology, Princess Margaret Cancer Centre, Toronto, Ontario, Canada. Hauptthemen laut MEDLINE: Hematopoietic Stem Cell Transplantation, Graft vs Host Disease, Neoplasms, Second Primary. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 38 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Second primary malignancies (SPMs) are a well‐recognized late complication of allogeneic haematopoietic stem cell transplantation (HSCT). This study aims to evaluate the impact of anti‐thymocyte globulin (ATG) and post‐transplant cyclophosphamide (PTCy) combination on the incidence of SPMs, compared to other graft‐versus‐host disease (GvHD) prophylactic regimens. Among 1418 evaluable patients with a median follow‐up of 6125 person‐years, 138 patients developed an SPM. The cumulative incidence at 5 years was 10.6% (95% CI: 9–13). The use of ATG–PTCy was independently associated with a reduced risk of developing SPM (Hazard Ratio [HR], 0.65; p = 0.02), while older patient age (HR, 1.10; p = 0.03) and moderate‐to‐severe chronic GvHD (HR, 1.54; p = 0.02) were associated with an increased risk of SPM. Compared to the general population, HSCT recipients were 2.45 times more likely to develop a malignancy ( p < 0.01). The 3‐year overall survival from the time of SPM diagnosis was 69.8% (95% CI: 61–77) with haematological SPM independently associated with inferior survival (HR: 2.40; 95% CI: 1.3–4.5; p < 0.01). Fifteen patients (11%) developed more than one SPM. In conclusion, ATG–PTCy appears to reduce the risk of SPM post‐HSCT. Active surveillance and screening for SPMs in transplant survivors are of paramount importance to ensure favourable outcomes.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Hematopoietic Stem Cell TransplantationGraft vs Host DiseaseNeoplasms, Second PrimaryHumansFemaleMaleMiddle AgedAdultAntilymphocyte SerumAgedAdolescentCyclophosphamideYoung AdultTransplantation, HomologousImmunosuppressive AgentsIncidenceChildFollow-Up Studies

Stichwörter der Autor:innen

ATGPTCyallogeneic haematopoietic cell transplantationchronic GvHDsecond primary malignancy

Substanzen

Antilymphocyte SerumCyclophosphamideImmunosuppressive Agents

Autor:innen und Institutionen

  • Hans Messner Allogeneic Transplant Program, Division of Medical Oncology and Haematology, Princess Margaret Cancer Centre, Toronto, Ontario, Canada.
  • Temerty Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada.
  • Department of Haematology, Oslo University Hospital, Oslo, Norway.

ORCID-Profile: Nihar Desai, Arjun D Law, Dennis D Kim, Fotios V Michelis

Zitieren

APA

Desai, N., Al-Shaibani, E., Alfaro-Moya, T., Law, A. D., Lam, W., Remberger, M., Pasic, I., Novitzky-Basso, I., Viswabandya, A., Kim, D. D., Kumar, R., Lipton, J. H., Mattsson, J., & Michelis, F. V. (2025). Impact of graft‐versus‐host disease prophylaxis on second primary malignancies after allogeneic haematopoietic stem cell transplantation. British Journal of Haematology. https://doi.org/10.1111/bjh.70006

Vancouver

Desai N, Al-Shaibani E, Alfaro-Moya T, Law AD, Lam W, Remberger M, et al. Impact of graft‐versus‐host disease prophylaxis on second primary malignancies after allogeneic haematopoietic stem cell transplantation. British Journal of Haematology. 2025. doi:10.1111/bjh.70006

BibTeX
@article{Desai2025,
  author = {Desai, Nihar and Al-Shaibani, Eshrak and Alfaro-Moya, Tommy and Law, Arjun D and Lam, Wilson and Remberger, Mats and Pasic, Ivan and Novitzky-Basso, Igor and Viswabandya, Auro and Kim, Dennis D and Kumar, Rajat and Lipton, Jeffrey H and Mattsson, Jonas and Michelis, Fotios V},
  title = {Impact of graft‐versus‐host disease prophylaxis on second primary malignancies after allogeneic haematopoietic stem cell transplantation},
  journal = {British Journal of Haematology},
  year = {2025},
  doi = {10.1111/bjh.70006}
}
Kostenlos starten →